The global Preventive Vaccines Market is estimated to be valued at US$ 46,258.9 Mn in 2022 and is expected to exhibit a CAGR of 9.4% over the forecast period (2023 to 2030), as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preventive vaccines help train and prepare the body's immune system to recognize and combat harmful microorganisms such as viruses and bacteria. It provides protection against infectious diseases without actually causing an infection. The preventive vaccines market is witnessing significant growth owing to the rising prevalence of infectious diseases across the globe. Preventive vaccines offer several advantages such as reduced healthcare expenditure, improved quality of life, increased productivity, and saves lives. There is a rising need for preventive vaccines due to increasing awareness regarding vaccination benefits.
Market key trends:
Rapid advancements in preventive vaccine technology is one of the major trends being witnessed in the global preventive vaccines market. Manufacturers are increasingly investing in research and development activities to develop more efficacious and novel preventive vaccine formulations. Growing focus on vaccines for diseases like AIDS, malaria and dengue fever is expected to drive the preventive vaccine technology advancements. Adoption of innovative vaccine production technologies like DNA vaccines and recombinant vaccine technology is also proving beneficial in developing improved preventive vaccines. Continuous focus on development of thermostable vaccines that do not require strict temperature-controlled transportation and storage is boosting the preventive vaccine market growth.
Porter's Analysis
Threat of new entrants: The threat of new entrants is moderate in the preventive vaccines market due to huge capital requirement high technological barrier and intellectual property rights.
Bargaining power of buyers: The bargaining power of buyers is high as the preventive vaccines market has several established global players offering substitutable products in the market.
Bargaining power of suppliers: The bargaining power of suppliers is moderate due to supplier concentration and differentiation in research & manufacturing capabilities.
Threat of new substitutes: The threat of new substitutes is low as no comparable alternative available currently for preventive vaccines.
Competitive rivalry: The competitive rivalry in the preventive vaccines market is high due to presence of global established players and product differentiation.
Key Takeaways
Global Preventive Vaccines Market Demand is expected to witness high growth, exhibiting CAGR of 9.4% over the forecast period, due to increasing immunization programs by various governments and non-profit organizations worldwide.
Regional analysis: North America dominated the preventive vaccines market in 2021 and is expected to maintain its dominance over the forecast period. This is attributed to presence of major market players, high awareness about immunization and presence of favorable reimbursement policies in the region. Asia Pacific is expected to grow at the fastest pace during the forecast period due to rising initiatives by governments as well as increasing healthcare investments are expected to drive the market growth.
Key players: Key players operating in the preventive vaccines market are Sanofi SA, Pfizer Inc., Novavax Inc., Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline PLC, Daiichi Sankyo Co. Ltd., Emergent BioSolutions Inc., AstraZeneca, and Takeda Pharmaceutical Company Limited, among others. Sanofi SA dominated the market and is focusing on development of new preventive vaccines for various infectious diseases.
Read More- https://www.ukwebwire.com/preventive-vaccines-market-size-share-analysis-and-growth/
Preventive Vaccines Market research study published by Profshare Market Research mainly focuses on the Covid 19 pandemic impact on market & its future outlook.
Research study has extensively worked on supply-demand analysis which is important parameter in industry.
Supplier analysis delivers very clear picture supply- demand scenario in the market.Analytical tools used while developing research studies includes SWOT analysis, market sizing, Porter’s 5 Forces model, PESTAL analysis.
Opportunities and threat analysis has gain significant importance in recent years primarily due to dynamic nature of industry.
Environment safety measure is covered in PESTAL analysis that informs clients about environment safety policies practicing by various countries globally.Research study has taken 2018 as base year while market data for 2014-17 is considered as historic data.
Precise analytical use of historic data is significant to calculate forecast value of market.
To order this detailed 250+ page report, please visit this link Key InclusionsA detailed assessment of the current market landscape, including information on type of developer (industry, non-industry, industry / non-industry), phase of development (phase I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead candidates, route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others), type of vaccine API (live, attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4 doses, 5 doses and 6 doses), target disease indication and target patient population (children, adults and seniors).A competitiveness analysis of preventive vaccine developers, taking into consideration supplier strength (based on company size and its experience in this field) and pipeline strength (based on the number of clinical-stage vaccine candidates, highest phase of development, number of compatible routes of administration, number of indications evaluated and target patient population).Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific.
Each profile includes a brief overview of the company, its year of establishment, location of headquarters, number of employees and financial information (if available).
In addition to this, the profile includes information on the various clinical-stage vaccine candidates developed by the company.
Further, we have provided the recent developments of the company and an informed future outlook.A detailed analysis of more than 1,400 completed, ongoing and planned clinical studies of preventive vaccines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, type of preventive vaccine (based on pathogen), target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), enrolled patients population and regional distribution.An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, Ebola virus disease, HIV/AIDS, malaria and zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape.
Further, we have provided the information on investments made and recent developments in the domain.An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in developing preventive vaccines.A case study on contract manufacturing landscape for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.
The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Route of AdministrationIntramuscularSubcutaneousOralIntravenousOthers Type of VaccinePneumococcal Conjugate VaccineHuman Papilloma Virus VaccineRotavirus VaccineInfluenza VaccineMMR VaccineTetanus and Diphtheria Booster VaccineVaricella VaccineDTaP-Hib-IPV VaccineDTaP-HepB-Hib-IPV VaccineOthers Type of Vaccine APILive, Attenuated VaccineInactivated VaccineConjugate VaccineSubunit VaccineToxoid VaccineOthers Target Patient PopulationPediatric PatientsAdults Key PlayersGlaxoSmithKlineMerckSanofi PasteurPfizerEmergent BioSolutionsCSLOthers To request sample pages, please visit this link Key Questions AnsweredWho are the leading developers of preventive vaccines?How big is the development pipeline and which new indications are coming in focus?Who are the key investors in the preventive vaccines market?What is the impact of COVID-19 on the demand for preventive vaccines?Which are the key / emerging CMOs, in different regions, that you can reach out to for your vaccine manufacturing requirements?How is the current and future opportunity likely to be distributed across key market segments?
